2581. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.
作者: Ganesh Raghu.;Juergen Behr.;Kevin K Brown.;Jim J Egan.;Steven M Kawut.;Kevin R Flaherty.;Fernando J Martinez.;Steven D Nathan.;Athol U Wells.;Harold R Collard.;Ulrich Costabel.;Luca Richeldi.;Joao de Andrade.;Nasreen Khalil.;Lake D Morrison.;David J Lederer.;Lixin Shao.;Xiaoming Li.;Patty S Pedersen.;A Bruce Montgomery.;Jason W Chien.;Thomas G O'Riordan.; .
来源: Ann Intern Med. 2013年158卷9期641-9页
Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of fibroblast foci. Endothelin-1 induces lung fibroblast proliferation and contractile activity via the endothelin A (ETA) receptor.
2582. Screening for and treatment of suicide risk relevant to primary care: a systematic review for the U.S. Preventive Services Task Force.
作者: Elizabeth O'Connor.;Bradley N Gaynes.;Brittany U Burda.;Clara Soh.;Evelyn P Whitlock.
来源: Ann Intern Med. 2013年158卷10期741-54页
In 2009, suicide accounted for 36 897 deaths in the United States.
2584. Comparative effectiveness of multivessel coronary bypass surgery and multivessel percutaneous coronary intervention: a cohort study.
作者: Mark A Hlatky.;Derek B Boothroyd.;Laurence Baker.;Dhruv S Kazi.;Matthew D Solomon.;Tara I Chang.;David Shilane.;Alan S Go.
来源: Ann Intern Med. 2013年158卷10期727-34页
Randomized trials of coronary artery bypass graft (CABG) surgery and percutaneous coronary intervention (PCI) suggest that patient characteristics modify the effect of treatment on mortality.
|